<?xml version='1.0' encoding='utf-8'?>
<document id="10725316"><sentence text="Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil."><entity charOffset="115-129" id="DDI-PubMed.10725316.s1.e0" text="5-fluorouracil" /><entity charOffset="144-170" id="DDI-PubMed.10725316.s1.e1" text="(E)-5-(2-Bromovinyl)uracil" /><pair ddi="false" e1="DDI-PubMed.10725316.s1.e0" e2="DDI-PubMed.10725316.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10725316.s1.e0" e2="DDI-PubMed.10725316.s1.e1" /></sentence><sentence text="The fatal drug-drug interaction between sorivudine, an antiviral drug, and 5-fluorouracil (5-FU) has been shown to be caused by a mechanism-based inhibition"><entity charOffset="40-50" id="DDI-PubMed.10725316.s2.e0" text="sorivudine" /><entity charOffset="75-89" id="DDI-PubMed.10725316.s2.e1" text="5-fluorouracil" /><entity charOffset="91-95" id="DDI-PubMed.10725316.s2.e2" text="5-FU" /><pair ddi="false" e1="DDI-PubMed.10725316.s2.e0" e2="DDI-PubMed.10725316.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10725316.s2.e0" e2="DDI-PubMed.10725316.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10725316.s2.e0" e2="DDI-PubMed.10725316.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10725316.s2.e1" e2="DDI-PubMed.10725316.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10725316.s2.e1" e2="DDI-PubMed.10725316.s2.e2" /></sentence><sentence text=" In this interaction, sorivudine is converted by gut flora to (E)-5-(2-bromovinyl)uracil (BVU), which is metabolically activated by dihydropyrimidine dehydrogenase (DPD), and the activated BVU irreversibly binds to DPD itself, thereby inactivating it"><entity charOffset="22-32" id="DDI-PubMed.10725316.s3.e0" text="sorivudine" /><entity charOffset="62-88" id="DDI-PubMed.10725316.s3.e1" text="(E)-5-(2-bromovinyl)uracil" /><entity charOffset="90-93" id="DDI-PubMed.10725316.s3.e2" text="BVU" /><entity charOffset="132-149" id="DDI-PubMed.10725316.s3.e3" text="dihydropyrimidine" /><entity charOffset="189-205" id="DDI-PubMed.10725316.s3.e4" text="BVU" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e0" e2="DDI-PubMed.10725316.s3.e0" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e0" e2="DDI-PubMed.10725316.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e0" e2="DDI-PubMed.10725316.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e0" e2="DDI-PubMed.10725316.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e0" e2="DDI-PubMed.10725316.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e1" e2="DDI-PubMed.10725316.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e1" e2="DDI-PubMed.10725316.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e1" e2="DDI-PubMed.10725316.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e1" e2="DDI-PubMed.10725316.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e2" e2="DDI-PubMed.10725316.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e2" e2="DDI-PubMed.10725316.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e2" e2="DDI-PubMed.10725316.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e3" e2="DDI-PubMed.10725316.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10725316.s3.e3" e2="DDI-PubMed.10725316.s3.e4" /></sentence><sentence text=" In an attempt to predict this interaction in vivo from in vitro data, inhibition of 5-FU metabolism by BVU was investigated by using rat and human hepatic cytosol and human recombinant DPD"><entity charOffset="85-89" id="DDI-PubMed.10725316.s4.e0" text="5-FU" /><entity charOffset="104-107" id="DDI-PubMed.10725316.s4.e1" text="BVU" /><pair ddi="false" e1="DDI-PubMed.10725316.s4.e0" e2="DDI-PubMed.10725316.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10725316.s4.e0" e2="DDI-PubMed.10725316.s4.e1" /></sentence><sentence text=" Whichever enzyme was used, increased inhibition was observed that depended on the preincubation time of BVU and enzyme in the presence of NADPH and BVU concentration"><entity charOffset="139-144" id="DDI-PubMed.10725316.s5.e0" text="NADPH" /><entity charOffset="105-109" id="DDI-PubMed.10725316.s5.e1" text="BVU" /><entity charOffset="149-153" id="DDI-PubMed.10725316.s5.e2" text="BVU" /><pair ddi="false" e1="DDI-PubMed.10725316.s5.e1" e2="DDI-PubMed.10725316.s5.e1" /><pair ddi="false" e1="DDI-PubMed.10725316.s5.e1" e2="DDI-PubMed.10725316.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10725316.s5.e1" e2="DDI-PubMed.10725316.s5.e2" /><pair ddi="false" e1="DDI-PubMed.10725316.s5.e0" e2="DDI-PubMed.10725316.s5.e0" /><pair ddi="false" e1="DDI-PubMed.10725316.s5.e0" e2="DDI-PubMed.10725316.s5.e2" /></sentence><sentence text=" The kinetic parameters obtained for inactivation represented by k(inact) and K'(app) were 2" /><sentence text="05 +/- 1" /><sentence text="52 min(-1), 69" /><sentence text="2 +/- 60" /><sentence text="8 microM (rat hepatic cytosol), 2" /><sentence text="39 +/- 0" /><sentence text="13 min(-1), 48" /><sentence text="6 +/- 11" /><sentence text="8 microM (human hepatic cytosol), and 0" /><sentence text="574 +/- 0" /><sentence text="121 min(-1), 2" /><sentence text="20 +/- 0" /><sentence text="57 microM (human recombinant DPD)" /><sentence text=" The drug-drug interaction in vivo was predicted quantitatively based on a physiologically based pharmacokinetic model, using pharmacokinetic parameters obtained from the literature and kinetic parameters for the enzyme inactivation obtained in the in vitro studies" /><sentence text=" In rats, DPD was predicted to be completely inactivated by administration of BVU and the area under the curve of 5-FU was predicted to increase 11-fold, which agreed well with the reported data"><entity charOffset="114-118" id="DDI-PubMed.10725316.s20.e0" text="5-FU" /><entity charOffset="78-81" id="DDI-PubMed.10725316.s20.e1" text="BVU" /><pair ddi="false" e1="DDI-PubMed.10725316.s20.e1" e2="DDI-PubMed.10725316.s20.e1" /><pair ddi="false" e1="DDI-PubMed.10725316.s20.e1" e2="DDI-PubMed.10725316.s20.e0" /></sentence><sentence text=" In humans, a 5-fold increase in the area under the curve of 5-FU was predicted after administration of sorivudine, 150 mg/day for 5 days"><entity charOffset="61-65" id="DDI-PubMed.10725316.s21.e0" text="5-FU" /><entity charOffset="104-114" id="DDI-PubMed.10725316.s21.e1" text="sorivudine" /><pair ddi="false" e1="DDI-PubMed.10725316.s21.e0" e2="DDI-PubMed.10725316.s21.e0" /><pair ddi="false" e1="DDI-PubMed.10725316.s21.e0" e2="DDI-PubMed.10725316.s21.e1" /></sentence><sentence text=" Mechanism-based inhibition of drug metabolism is supposed to be very dangerous" /><sentence text=" We propose that such in vitro studies should be carried out during the drug-developing phase so that in vivo drug-drug interactions can be predicted" /><sentence text="" /></document>